Oncology

CancerNetwork® spoke with Neelam and Sanju Sinha of the National Cancer Institute about their research into sex differences associated with using tumor mutational burden to predict response to PD-1 inhibition.

CancerNetwork® sat down with Health and Wellness expert Sonia Jhas to discuss best practices for avoiding unhealthy eating habits on a demanding schedule.

Low-grade, manageable treatment-emergent adverse effects and low rates of discontinuation were associated with the RET inhibitor selpercatinib as therapy for patients with RET-altered advanced solid tumors who were treated on the LIBRETTO-001 trial.

Look back at some of the important news and notes from last week in the world of oncology, featuring articles from the latest issue of the Journal ONCOLOGY®.

During an After Hours segment of Medical World News®, Nina Shah, MD, spoke about her new passion for Peloton, the convenience of working out from home, and the importance of getting out of the office for personal health and wellness.

According to the research, there are important components and factors missing from the scale commonly used to measure a clinician’s quality of life.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring articles about the virtual AACR Annual Meeting 2021, breast cancer, prostate cancer, and lung cancer.

CancerNetwork® spoke with Vivek Subbiah, MD, during the virtual American Association for Cancer Research Annual Meeting 2021 to discuss the most important data to come out of the meeting regarding therapy for tumors harboring KRAS mutations.

The majority of independently adjudicated interstitial lung disease cases associated with the antibody-drug conjugate were low grade and occurred within the first 12 months of treatment.

Zenocutuzumab has been shown to block the growth and cause the death of NRG1 fusion–positive cell lines, and to induce tumor shrinkage and durable tumor regression in multiple cancers when used in NRG1 fusion–positive patient-derived xenografts.

In an analysis of a cohort of patients treated with atezolizumab in the myPathway trial, a tumor mutational burden cutoff of 16 mutations per megabase or higher was key for achieving durable responses in various solid tumors.

CancerNetwork®’s podcast features an interview with the chairman and CEO of Enveric Biosciences, David Johnson, to discuss the latest in their development of endocannabinoid products.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news from the FDA and articles about prostate cancer, ovarian cancer, and more.

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.

CancerNetwork® reports on updates in prevention and earlier diagnosis of colorectal, breast, and other cancers.

A presentation from the AACR Virtual Meeting: COVID-19 and Cancer detailed a literature review of natural therapeutics and remedies to combat the SARS CoV-2 virus.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring articles about breast cancer, prostate cancer, and more.

Data investigating the predictive capabilities of high tumor mutation burden found it to be predictive of response to immune checkpoint blockade in some, but not all, types of cancers.

The American Cancer Society Cancer Action Network partnered with the National Comprehensive Cancer Network and the National Minority Quality Forum to produce recommendations addressing issues regarding health equity and disparities among minority patients with cancer.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about prostate cancer, breast cancer, precision medicine, and gynecologic cancers.

Based on results of a cohort study that examined randomized clinical trials in 3 times periods, it is evident that efficacy measures and funding sources have dramatically changed over time.

CancerNetwork® spoke with Tzvia Bader about barriers between patients and appropriate clinical trials and how to combat these issues.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, molecular profiling, ovarian cancer, and more.

Compugen announced updated data surrounding the investigational therapeutic antibody, COM701, as monotherapy and in combination with nivolumab.

A novel imaging technology was cleared by the FDA to detect polyps with neoplastic potential during conduct of colonoscopy that aligns with pathological assessment with greater than 90% predictive ability.

Recently reported results from the ongoing phase 1 TUNINTIL trial of the oncolytic virus TILT-123 show safety of this approach.

Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about breast cancer, prostate cancer, and urothelial cancer.

ONCOLOGY co–Editor-in-Chief Julie M. Vose, MD, MBA, details how underrepresentation of racial and ethnic minorities in clinical trials negatively impacts the medical community and calls for greater inclusion by removing some barriers to participation.

CancerNetwork® sat down with Trevor J. Pugh, PhD, to discuss a novel protocol for detecting mismatch repair deficiency.

Indications for pembrolizumab, nivolumab, and atezolizumab are set for examination under the FDA’s Oncologic Drugs Advisory Committee for indications granted accelerated approval in breast, urothelial, gastric, and liver cancers.